Novel management of glioma by molecular therapies, a review article

Abstract

The most frequent type of brain tumors is Glioma which commonly appears initially in the neuroglia in the central nervous system. They grow steadily and generally do not outspread to neighboring tissue of the brain. By applying dominant remedial regimens, the patients would have negligible survival rates. Despite the achieved advances in conventional glioma therapy, it proved that a proper medication for glioma is not easily reachable. The glioma penetration nature and accumulate resistance considerably limit the remedial options. Superior explanation of the glioma complex pathobiology and characterization of biological proteogenomic may finally open new approaches for the outlining of extra artificial and impressive combination regimens. This aim could be achieved by exclusively outfitting advanced techniques of neuroimaging, terminating synthesis of DNA via genes that activated via prodrugs, experimental technique of gene therapy via conciliating genes of gliomagenesis, targeting miRNA-mRNA activity of oncogenic, applying stem cell therapy for combining inhibitors of Hedgehog-Gli, adaptive transmission of chimeric immunoreceptors T cells, incorporate inhibitors of regulators of the immune system with conventional remedial modalities and additionally using tumor cell lysates as sources of antigen for efficient evacuation of particular stem cells of tumor via cytotoxic T lymphocytes. Consequently, in this study the authors trying to survey the latest progressions related to the molecular procedures connected with the formation of glial tumors in addition to the radiation, surgery and chemotherapy limitations. Additionally, the novel strategies of molecular remedies and their procedure for the prosperous treatment of glioma will be discussed.

Incidence of Gliomas in Municipalities of Zenica - Doboj Canton in Bosnia and Herzegovina - A 10-Year Study

“…Neuroepithelial neoplasms are always primary tumors and can be further classified into more subcategories as astrocytic tumors (pilocytic astrocytoma, diffuse infiltrating astrocytoma and anaplastic astrocytoma), oligodendroglial and mixed glioma tumors (Grade II or Grade III glioma) and ependymal type gliomas 14 . The most malignant form of all these gliomas is called glioblastoma multiforme (GBM) 15 . It can arise de novo or as malignant proliferation from some other type of lower grade glioma.…”

An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach

“…Also, high recurrence rates of GBM, the incidence of new genetic mutations, and invasive phenotypes in the recurrence activity have exacerbated the issue of treating recurrent GBM [31]. Therefore, it would be highly effective to both use novel molecular and clinical ways to treatment GBM and discover more effective molecular targets for treatment [46].…”

Dual‐Knockout of Mutant Isocitrate Dehydrogenase 1 and 2 Subtypes Towards Glioma Therapy: Structural Mechanistic Insights on the Role of Vorasidenib

“…For decades, the most common therapeutic approaches used for the treatment of glioma have included surgery, chemotherapy, and radiotherapy [11,12] . Despite the technological advancements, the rate of glioma incidences has not declined, and finding a cure remains a challenge.…”